TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) stock intrinsic value fair value estimate & owner earnings analysis

Teva is an Israeli-headquartered drug maker: one of the world's largest generic medicine producers (about 6.5% of all U.S. generic prescriptions) plus a growing branded business led by AUSTEDO for tardive dyskinesia and Huntington's chorea, AJOVY for migraine and UZEDY for schizophrenia. Revenue was $17.3 billion in 2025. From September 2026 Teva's ordinary shares trade directly on the NYSE in place of the old depositary shares; values here are per share on about 1,165 million diluted shares. Earning power. We measure the cash the business generates for owners: operating cash flow with short-term swings in working capital stripped out, the cost of employee stock awards deducted, and capital spending needed to maintain the plants deducted. Removing working-capital swings matters a great deal for Teva: it sells receivables through a securitization program whose collections it reports outside operating cash flow, and it pays down legal settlements out of accrued liabilities, so reported operating cash flow ($0.8 to $1.6 billion a year since 2019) understates the business. On our measure, owner earnings per share were $0.92 (2019), $2.46 (2020), $1.64 (2021), a loss of $0.39 (2022, the year the opioid settlement was booked), $0.74 (2023), $0.96 (2024) and $2.05 (2025). Adding back roughly $0.95-1.1 billion of cash interest gives the cash the business makes before its lenders: a median of about $1.85 per share, or about $2.15 billion a year, over 2019-2025. We start from 2019 because the earlier years still carried Copaxone's exclusivity and a much larger, pre-restructuring generics book. That earlier period describes a different business. Large impairments ($1.0-6.5 billion in several years) and $0.6-0.8 billion a year of intangible amortization are added back automatically; the decay those charges represent is carried in the growth path below, chiefly the 2033 AUSTEDO generic entry. What changed. The 2025 figure jumped to $2.05 per share, but about $500 million of that was a one-time milestone payment for duvakitug, and the first half of 2026 shows U.S. generics down 31% in the second quarter as competition hit generic Revlimid, a $724 million write-off on the Emalex acquisition, and a further $230 million of legal provisions. So, although owner earnings grew sharply in 2025, our base case starts year one at about $2.1 billion of pre-interest cash, below the 2025 level of about $3.3 billion. Against that, AUSTEDO grew 35% in 2025 to $2.2 billion in the U.S. and another 40% in the second quarter of 2026, and AJOVY and UZEDY are growing fast; together these brands now exceed $1 billion a quarter. Our previous estimate was built on a different cash-flow basis and is not comparable. What Teva owes. Borrowings were $16.6 billion at June 30, 2026 against $3.7 billion of cash, of which we treat about $1.5 billion as needed to run a business of this size. Ahead of shareholders there is also a $4.75 billion provision for legal settlements, chiefly the nationwide opioid agreement of up to $4.25 billion spread over 13 years (including up to $1.2 billion of generic Narcan supply). We treat that backlog as a debt-like claim worth about $3.9 billion today, because those payments are stripped out of our cash measure. Total claims are therefore about $18.3 billion. About $4.5 billion of debt is due within a year, but Teva has been refinancing on schedule (a $2.3 billion note issue in 2025), cut debt from $17.8 billion to $16.8 billion during 2025, and was upgraded to investment grade by Fitch in 2026. In every case below, pre-interest cash comfortably exceeds the roughly $0.95 billion annual interest bill. Base case: about $2.1-2.3 billion a year of pre-interest cash for seven years. AUSTEDO, AJOVY and UZEDY volume growth, a demonstrated multi-year record, offsets continued erosion in generic Revlimid and the January 2027 Medicare negotiated price on AUSTEDO. When AUSTEDO generics enter in April 2033 under the Lupin and Aurobindo settlements, cash steps down to about $1.5 billion. That is what the generics, biosimilar and smaller-brands franchise has sustained by itself for decades. No pipeline success (duvakitug, olanzapine LAI, ecopipam) is credited, because none is approved. The business is worth about $29.6 billion; after $18.3 billion of claims that leaves about $11.2 billion, or $9.66 per share. Bear case: a repeat of the 2017-2019 U.S. generic price-deflation episode, when pricing collapsed and Teva's gross profit fell from $10.6 billion to $7.5 billion. It hits at the same time as the 2027 AUSTEDO Medicare price cut and further Revlimid erosion, so pre-interest cash falls from $2.0 billion to about $1.2 billion for two to three years (close to the 2019 and 2022 trough levels) and recovers only partly before AUSTEDO generics arrive. Long-run cash settles at about $0.9 billion. The business is worth about $19.1 billion, barely above the $18.3 billion owed, leaving roughly $0.8 billion, or $0.67 per share. In this case shareholders own almost nothing after the lenders and settlement claimants are paid. Bull case: the three growth brands keep growing on their current trajectory into 2029, and the 2025 cash level of about $3.2 billion pre-interest is sustained to the AUSTEDO patent cliff before stepping down to about $2.3 billion. The business is worth about $42.6 billion, leaving about $24.3 billion, or $20.83 per share. Margin-of-safety price. How sure are we of the earnings level? Only moderately. Teva's cash generation has swung from a $437 million loss to $2.4 billion within four years, partly because of legal settlements and partly because of working-capital management that the company itself says it adjusts to manage leverage. The worst plausible outcome is a generic pricing collapse coinciding with the AUSTEDO price cut and a new wave of litigation. With about $18 billion of claims ranking ahead of shareholders, the equity would be nearly wiped out, as the bear case shows, though the debt is spread across maturities averaging 5.6 years and the hard assets (plants and a global generics portfolio) have kept producing cash through every past crisis. If AUSTEDO growth stalls or new opioid-style liabilities emerge, the shares are worth perhaps $3-5. Teva pays no dividend, so any return in the cases has to come from debt paydown and growth in the branded medicines. At about $1.2-1.4 billion a year of cash after interest, each year of steady debt reduction adds roughly a dollar per share to what owners keep. From $4.50, if the base case plays out over about five years, value per share would reach roughly $12-13, which implies about a 20% annual return. From that price, a fall back to the bear case implies a loss of about 85%; the price rests on the base outcome being so much larger and the claims now shrinking rather than growing. The margin-of-safety price is $4.50, a level where the five-year return in the base case works on the median outcome without assuming any pipeline success. Caveats: the split of the $4.75 billion legal provision between the opioid backlog and other matters is our reading of the filings, and the cash needed to run the business is our estimate. The first-half 2026 figures come from Teva's second-quarter 2026 report rather than an audited annual statement.